Accessibility Tools

Open label study for treatment of Ménière's Disease

Sound Pharmaceuticals, Inc.

  • astellas logoCandidates must be between 18-75 years of age
  • Has a diagnosis of probable or definite Ménière's Disease
  • At least two of three active symptoms (fluctuating hearing; tinnitus; aural fullness; vertigo or dizziness) of Ménière's disease.
  • Cannot have significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, neurological or psychiatric disease.
    • Length of study: 6 or 12 months
    • Oral medication
  • Study drug, exams, diagnostic tests, and blood work are covered and are free of charge to the patient
  • Compensation for time and travel

Study conducted by:

Principal Investigator – Mark H. Widick, MD
Sub-Investigator – Diana del Valle, MD
5130 Linton Blvd., Suite E2, Delray Beach, Florida 33484

– and –

Principal Investigator - Joshua P. Light, MD
Sub-Investigators – Valentina Akyol, PA-C, Julie Daugherty, PhD, NP-C and Karen Reyes, APRN

9868 State Road 7, US 441, Suite 345, Boynton Beach, Florida 33472
1800 West Woolbright Rd, Suite 201, Boynton Beach, Florida 33426

If you want further information concerning this study, contact

  • Delphine Coles at 561-939-0186 or This email address is being protected from spambots. You need JavaScript enabled to view it.